Get notified when PRLD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- The Expected Net Proceeds From This Offering Will Not Be Sufficient For US to Fund Our Current Product Candidates or Any Future Product Candidate Through Regulatory Approval, and We Will Need to Raise Substantial Additional Capital (new) — The company explicitly discloses that the offering proceeds are insufficient to reach regulatory approval, indicating ongoing liquidity risk and likely future dilution.
Prelude Therapeutics launches at-the-market offering of up to $25M at $3.60/share
Filed March 12, 2026 · ~1 min read
Key Changes
-
high
Prelude Therapeutics is selling up to $25.0 million of common stock in an at-the-market offering under a Sales Agreement with Jefferies.
Use of Proceeds verify on EDGAR → -
medium
The offering price is $3.60 per share, the last reported sale price on Nasdaq on March 10, 2026.
The Offering verify on EDGAR → -
high
New investors will incur immediate dilution of $2.28 per share, as the as-adjusted net tangible book value is $1.32 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (IMMR 10-Q) is open in full — no account needed.
Partner
Trade PRLD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify